Indivior Raises Full-Year Guidance on Strong SUBLOCADE Growth — Indivior Pharmaceuticals Inc.

Event summary

Q2 2026 total net revenue up 14% YoY to $343 million, with SUBLOCADE revenue growing 21% YoY to $253 million.
Record quarterly GAAP net income of $122 million and non-GAAP net income of $142 million.
Adjusted EBITDA up 111% YoY to $186 million, driven by operational execution in Phase II – Accelerate.
Repurchased approximately 4.7 million shares for $175 million in Q2 2026.
Proposed merger with Supernus expected to close in Q4 2026.

The big picture

Indivior's strong Q2 performance underscores the strategic focus on its SUBLOCADE product, a key player in opioid use disorder treatment. The proposed merger with Supernus aims to create a diversified CNS-focused biopharmaceutical company, reflecting broader industry trends toward consolidation and specialization in high-growth therapeutic areas.

What we're watching

Merger Integration: The pace at which Indivior and Supernus can integrate operations will determine the realization of anticipated synergies.
SUBLOCADE Growth: Whether Indivior can sustain the 21% YoY growth in SUBLOCADE revenue amid potential competitive pressures.
Financial Discipline: How Indivior balances aggressive share repurchases with investment in future growth drivers post-merger.